TY - JOUR T1 - Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). JO - Journal of Clinical Oncology PY - 2013/06/20 AU - James ND AU - Pirrie S AU - Barton D AU - Brown JE AU - Billingham L AU - Collins SI AU - Daunton A AU - Birtle AJ AU - Chakraborti PR AU - Ford D AU - Hussain SA et al ED - DO - DOI: 10.1200/jco.2013.31.18_suppl.lba5000 PB - American Society of Clinical Oncology (ASCO) VL - 31 IS - 18_suppl SP - LBA5000 EP - LBA5000 Y2 - 2025/07/17 ER -